High Q Technologies has expanded its quantum-enabled electron paramagnetic resonance platform to accelerate Alzheimer's disease drug discovery by analyzing protein motion in unprecedented detail. The company's Fathom system leverages quantum sensors to capture multiple protein configurations simultaneously, providing a more comprehensive understanding of protein behavior and interactions with potential drug candidates. This advancement enables researchers to better identify promising compounds and optimize their design. By partnering with contract research organization Creative Biostructure, High Q Technologies aims to further enhance the capabilities of its platform. The use of quantum-enabled EPR has the potential to significantly accelerate the discovery of effective treatments for neurodegenerative disorders, making it a crucial development in the field of drug discovery1. This matters to practitioners because it could lead to breakthroughs in the treatment of Alzheimer's disease, a condition that has long been notoriously difficult to address.